Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.

European journal of cancer (Oxford, England : 1990) - 1 Nov 2017

Vanderstichele Adriaan, Busschaert Pieter, Olbrecht Siel, Lambrechts Diether, Vergote Ignace

Abstract excerpt

DNA repair deficiency is a common hallmark of many cancers and is increasingly recognised as a target for cancer therapeutics. Selecting patients for these treatments requires a functional assessment of multiple redundant DNA repair pathways. With the advent of whole-genome sequencing of cancer genomes, it is increasingly recognised that multiple signatures of mutational and chromosomal alterations can be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Chromosomes, Human

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Breaks, Double-Stranded

Share to Ovarian Neoplasms

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Recombinational DNA Repair

Share to Transcriptome

Source

Identifiers

PMID: 28950147
DOI: 10.1016/j.ejca.2017.08.029

Genes

BRCA1
CDK12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.PMID 28950147Read ↗

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsSemantic proximity Read ↗

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerSemantic proximity Read ↗

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureSemantic proximity Read ↗

Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.Semantic proximity Read ↗

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literatureSemantic proximity Read ↗

Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.Semantic proximity Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read ↗

Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.